---
title: "Weekly Recap | Oruka Therapeutics +2.79%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299513915.md"
description: "Oruka Therapeutics (ORKA) rose 2.79% this week to close at $94.96. The S&P 500 slipped 0.08% over the same period, leaving the stock roughly 2.87 percentage points ahead. Day to day, Monday opened higher and touched $97.48 before Tuesday pulled back to a weekly low of $90.41. The next three sessions recovered, with Thursday reaching $98.29, before Friday faded from an early high to settle at $94.96. The stock swung 8.51% on the week with heavier-than-usual turnover."
datetime: "2026-09-19T06:39:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299513915.md)
  - [en](https://longbridge.com/en/news/299513915.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299513915.md)
generator: "portal-rs"
---

# Weekly Recap | Oruka Therapeutics +2.79%, most brokers rate it buy

## The Week

Oruka Therapeutics (ORKA) rose 2.79% this week to close at $94.96. The S&P 500 slipped 0.08% over the same period, leaving the stock roughly 2.87 percentage points ahead. Day to day, Monday opened higher and touched $97.48 before Tuesday pulled back to a weekly low of $90.41. The next three sessions recovered, with Thursday reaching $98.29, before Friday faded from an early high to settle at $94.96. The stock swung 8.51% on the week with heavier-than-usual turnover. There was no major company-specific catalyst; the move tracked broader sentiment in biotech.

## Analyst Ratings

Thirteen analysts currently cover the stock: 11 rate it buy and 2 rate it outperform, with no hold, underperform or sell ratings. The consensus rating is strong buy and the consensus target is $155, about 63.23% above the latest close of $94.96. Targets range from $117 to $200, a fairly wide spread. Within the biotechnology sector, the stock ranks 91st out of 501 names, in the top fifth by analyst rating.

## The Week Ahead

The macro calendar is busy next week. Tuesday brings the Richmond Fed composite index, Wednesday has EIA weekly crude and Cushing inventories, and Thursday features initial jobless claims, the current account balance, new home sales and natural gas storage data. No earnings or major company announcements are scheduled. The focus is likely to stay on how macro data shapes risk appetite across biotech.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ORKA.US](https://longbridge.com/en/quote/ORKA.US.md)

## Related News & Research

- [Oruka Therapeutics General Counsel Paul T Quinlan Sells $706,734.83 in Common Shares](https://longbridge.com/en/news/302482391.md)
- [BTIG reiterates Buy rating on Oruka Therapeutics, $151 price target](https://longbridge.com/en/news/302269495.md)
- [Oruka Therapeutics Chief Medical Officer Joana Goncalves Reports Sale of Common Shares Worth $523,647.721](https://longbridge.com/en/news/302028900.md)
- [Nebius Says It Faces Less Debt Risk Than CoreWeave As AI Spending Fears Mount](https://longbridge.com/en/news/302598593.md)
- [Warren Buffett's Successor, Greg Abel, Just Went Shopping in the Tech Sector Again!](https://longbridge.com/en/news/302535520.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**